Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. These symptoms affect people in different ways and have been demonstrated to broadly impact physical, mental, and cognitive health. This is called Long COVID. Currently, there are no treatments available to address the issues that patients experience but anti-viral medications have been suggested as being potentially effective. This study will recruit patients that have confirmed long COVID and participants will undertake a series of tests to determine their symptoms and the impact that their condition has had on their bodily systems. The total duration of each participant's involvement is approximately 8 weeks, and this will involve 13 visits (15 visits if taking part in Exeter) at the closest study location (Derby or Exeter). Initial assessments are conducted over three separate visits and then all participants will be scheduled to receive five consecutive days of a medication that has been identified as having the potential to reduce the impact of Long COVID. Following a period of 28 days, participants will be invited to repeat the same tests that were conducted before receiving the medication so that it can be determined how well the drug has worked. In this study we are specifically collecting information to understand how feasible this medication could be to help patients improve their condition and this will help us to determine how likely this drug is able to be used within the wider Long COVID community.
The medication that will be used within this study is an existing anti-viral medication (Remdesivir). If we find patients are able to tolerate the treatment and the research tasks we will use this information to conduct a larger trial to determine how well this drug can be used to reduce the impact of Long COVID in a greater number of patients.

开始日期2024-09-23

申办/合作机构

University of Derby

[+5]

NCT06394921 / CompletedN/AIIT

Interrogative Approaches Identify Causes of Physical Impairment in Those Affected by Post COVID-19 Morbidity (Long COVID) - an International Multicenter Observational Study

The value of clinical cardiopulmonary exercise testing (CPET) within healthcare settings has been established in the last decade. CPET methods remain highly relevant in the COVID-19 endemic phase and should be used to assess those recovering from COVID-19 (SARS-CoV-2) infection. This diagnostic tool could play an integral role in disease prognostication and evaluate the integrative response to incremental exercise. Date from such assessments can enable practitioners to characterise cardio-respiratory fitness and identify reasons for physical impairment or abnormal cardio-respiratory function. More than 50% of patients admitted to hospital will experience cardiorespiratory issues and significant morbidity during their recovery and will require significant rehabilitative support. In this context, measurements obtained from an assessment of cardio-respiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardio-respiratory function. Current approaches to rehabilitation are being developed on existing knowledge from Severe Acute Respiratory Syndrome (SARS) and Acute Respiratory Distress Syndrome (ARDS) related illness. These provide important insight but do not provide insight into the novel challenges provided by COVID-19.

开始日期2023-03-01

申办/合作机构

Sheffield Hallam University

[+6]

NCT05224362 / CompletedN/AIIT

Acute Effects of Elastic Band Resistance Applied to the Hip and Chest Region on Postural Stability and Physical Function Before, Immediately and up to 30 Min After Exercise in Physically Active Older Adults

Current balance and stability interventions have been shown to improve balance through targeting balance impairments and retraining effects. However, there are key facilitators and barriers 'that older adults may face to participate in such interventions'. Additionally, physical activity interventions fail to integrate older adults into the co-design and co-production of PA interventions. The study will aim to identify the impact and practicalities of an exercise intervention in older adults by performing pre selected exercises with an elastic resistance band attached at the hip and chest region to challenge balance. Static posturography will assess the impacts of the exercise intervention on balance and stability.
Researcher led interviews will focus on the participants perceptions of the activities and decision making of exercise selection by selecting components that they are confident to perform which is a key element to creating a practical and enjoyable exercise programme for the older population. This will co-create an intervention that is accessible, acceptable, and appropriate for older adults.
The study will establish the physical impact and practicalities of a novel elastic band resistance exercise intervention in older adults by performing force plate posturography and researcher led interviews that will focus on the participants perceptions of the activities and intensity levels to co-create an intervention that is accessible, acceptable, and appropriate for older adults.

开始日期2022-04-06

申办/合作机构

University of Derby

100 项与 University of Derby 相关的临床结果

登录后查看更多信息

0 项与 University of Derby 相关的专利（医药）

登录后查看更多信息

707

项与 University of Derby 相关的文献（医药）

2024-11-01·NUCLEAR ENGINEERING AND DESIGN

Preface for special issue “NFT-10: UK and ireland” − nuclear fission technology in UK and Ireland

作者: Margulis, Marat

2024-08-01·NUCLEAR ENGINEERING AND DESIGN

Zero power reactors in support of current and future nuclear power systems

作者: Margulis, Marat

Zero-power reactors stand as indispensable tools for shaping the future of the nuclear industry.Addressing safety concerns, advancing reactor technol., mitigating proliferation risks, fostering education, and promoting economic viability, these reactors hold the key to unlocking the full potential of nuclear energy in a sustainable and responsible manner.As the world seeks cleaner and more efficient energy solutions, the importance of zero-power reactors cannot be overstated in charting the course for the nuclear industry′s future.The paper presents a short history of the various zero-power/zero-energy exptl. facilities constructed and used worldwide.Many of the names seemed to be lost to history and archives, which means that all the exptl. data carried in the those facilities is lost as well.However, re-introducing the various names can spark an interest in "digging up" and revisit experiments of the past, which can help in the design of experiments and new systems in the future.It is clear that a new exptl. facility should be built.The next frontier in zero-power reactor design envisions a design for versatility, this future concept addresses diverse energy needs while contributing to a sustainable and responsible nuclear energy landscape.This was demonstrated in the framework of the Zero-power Exptl. PHYsics Reactor design proposed by French Atomic Energy Commission.

2024-08-01·PRECAMBRIAN RESEARCH

The late Archaean granite paradox: A case study from the Zimbabwe Craton

作者: Chagondah, Godfrey ; Hofmann, Axel ; Rollinson, Hugh

Late- to post-tectonic high-K granites are found in many Archaean cratons and are thought to be the product of a major, crustal-scale melting event in the underlying TTG crust leading to the stabilization of the craton.However, despite the TTG melting model being an obvious explanation for the origin of late-Archaean high-K post-tectonic granites, exptl. studies show that TTGs are insufficiently fertile to produce large volumes of potassic granites.This is the late Archaean granite paradox.Here we argue that the paradox can be resolved if the TTG protolith is more potassic than might be expected from a straightforward partial melt of an Archaean basalt.We propose that a likely fertile protolith for late Archaean granites is TTG crust which has incorporated a partial melt of older felsic crust during its emplacement.This hypothesis is validated with a case study from the Neoarchaean rocks of the Zimbabwe Craton.This paradox reflects a more fundamental problem when considering the origin of Archaean TTGs, for the ′enriched′ basaltic protolith invoked in many models of TTG genesis is not abundant in Archaean terrains, nor should it be if the basaltic protolith is a melt of primitive or depleted mantle.This means that fertile, K-rich, TTGs are not simply the product of the melting of a basaltic protolith, but involve an addnl. process.Three models of TTG petrogenesis are discussed which might lead to K-enrichment in the melt - the hydrothermal potassic enrichment of the basaltic protolith and the influences of fractional crystallization and/or crustal contamination on the TTG magmas.We conclude that to produce a sufficiently fertile, K-rich TTG source in the Zimbabwe Craton the contribution of a melt phase from older TTG crust is most consistent with the major and trace element and isotopic geochem.

项与 University of Derby 相关的新闻（医药）

2024-01-03

·PRNewswire

Biomarker and Companion Diagnostics Annual 2 Day Conference - London, United Kingdom (March 7-8th, 2024)

DUBLIN, Jan. 3, 2024 /PRNewswire/ -- The "5th Annual Biomarker and Companion Diagnostics Conference" has been added to ResearchAndMarkets.com's offering. Leveraging Next-Gen Technologies Beyond Conventional Biomarker Drug Discovery The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials. 20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS-based CDx and the Importance of imaging biomarkers for precision medicine. Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in a one-on-one session. Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th - 8th March 2024 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers. Key Highlights: Clinical biomarker identification and qualification Biomarkers and personalized medicine Assay development and validation NGS and novel technologies in biomarker discovery Commercialization of biomarkers in therapeutic and CDx applications Speakers Debora Souza Da Costa, Biosample Operations Specialist, Roche Stephanie Traub, Associate Director, Translational Biomarkers & Bioanalysis, UCB Ron Wolbert, Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers & Bioanalysis, UCB Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB Smiths Lueong, Head, Early Detection and Biomarkers, The Cameroon Consortium for Translational Cancer Research Christian Garde, Scientific Director, Bioinformatics, Evaxion Biotech A/S Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG Shidong Jia, Founder, CEO, Predicine Liying Yan, President, Scientist, EpigenDx Robert Watson, Clinical Lecturer, University of Oxford Radha Krishnan, Executive Director and Clinical Pathology Lead, Merck Jelmar Quist, Cancer Bioinformatician, King's College London Jessica Fowler, Market Development Executive, Roche Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby Christopher Peters, Clinical Senior Lecturer, Imperial College London For more information about this conference visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

2022-11-29

·GlobeNewswire-Health Care

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December. Helsinn will be presenting a poster on the ongoing MyRisk international trial, assessing whether the administration of a combined treatment of NEPA (Fixed Combination of Netupitant/Palonosetron) and dexamethasone is more effective than the current standard of care prophylaxis1-2-3 (a combination of 5-HT3 receptor antagonist and dexamethasone) in preventing Chemotherapy-induced Nausea and Vomiting (CINV) in patients at increased risk of emesis receiving moderately emetogenic chemotherapy. Full details of the poster presentation are below: Title: Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for Preventing Chemotherapy-induced Nausea and Vomiting (CINV) in Patients at Increased Emetic Risk Receiving Moderately Emetogenic ChemotherapyAuthor: Alex Molassiotis, Matti Aapro, Alessandro Alonzi, Marika Chrápavá, Karin Jordan Eric J. Roeland, Lee Schwartzberg, Carole Terrasanta, Silvia Olivari Tilola, George DranitsarisSession: Poster session, 03 December, 18:00 – 18:45Abstract ID: NCT04817189 Dr Silvia Sebastiani, Helsinn Group Head of Medical Affairs, commented: “We are pleased to present the design of this important ongoing study at the ESMO Asia congress. Despite the array of effective antiemetics, CINV still represents a huge unmet need in clinical practice. To further the goal of CINV prevention for all patients undergoing emetogenic chemotherapy, it is important to explore ways to optimize antiemetic selection, including exploring factors that may increase CINV risk for patients.” Prof. Alex Molassiotis, Pro Vice Chancellor and Dean, University of Derby, UK and Scientific Lead of the MyRisk study added: “In patients receiving moderately emetogenic chemotherapy (MEC), antiemetic guidelines generally recommend a setron + dexamethasone (DEX). However, one guideline committee (the National Comprehensive Cancer Network (“NCCN”)) recognized that this approach is inadequate prophylaxis for many patients and included an NK1 RA-containing option selectively for those with individual emetic risk factors2. MyRisk is the first study prospectively exploring the role of NK1 RA-containing regimen, Akynzeo in this case, in patients receiving MEC who have additional risk factors.” About AKYNZEO® AKYNZEO® is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. A single dose of AKYNZEO® given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days. For additional information please see the EU Summary of Product Characteristics. About AKYNZEO® in the US INDICATION AKYNZEO® (netupitant 300mg/palonosetron 0.5mg) capsules was approved in October 2014 in the United States and is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO® (fosnetupitant 235mg/palonosetron 0.25) for injection was approved in April 2018 and AKYNZEO® injection was approved in May 2020 in the United States. Each is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use: AKYNZEO® for injection and AKYNZEO® injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO® is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. IMPORTANT SAFETY INFORMATION Warnings and Precautions: Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO®, with or without known hypersensitivity to other 5-HT3 receptor antagonists. Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO® and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO® is used concomitantly with other serotonergic drugs. Adverse Reactions: Most common adverse reactions for AKYNZEO®: headache, asthenia, dyspepsia, fatigue, constipation and erythema. Drug-drug Interactions: Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4 isoenzyme. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO®. The inhibitory effect on CYP3A4 can last for multiple days. Dexamethasone doses should be reduced when given with AKYNZEO®. A more than two-fold increase in the systemic exposure of dexamethasone was observed 4 days after a single dose of netupitant or a single infusion of fosnetupitant. Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO®. When administered with netupitant, the systemic exposure to midazolam was significantly increased. Avoid concomitant use of AKYNZEO® in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO®. Use in Specific Populations: Avoid use of AKYNZEO® in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease. Avoid use in pregnancy, limited data is available, may cause fetal harm. For more information about AKYNZEO® please see the full US Prescribing Information About Helsinn Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases. Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. Helsinn’s unique business model enables it to in-license or acquire assets at a late stage of development. It has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd. Helsinn plays an active and central role in promoting social transformation in favor of people and the environment. Sustainability is at the heart of everything we do, which is reinforced in the company’s strategic plan by a commitment to sustainable growth. To learn more about Helsinn please visit www.helsinn.com References: 1 Roila F. et al. Ann Oncol. 2016 Sep;27(suppl 5):v119-v133. MASCC/ESMO Antiemetic Guideline 2016 V.1.4 last update July 2019. Available at: http://www.mascc.org/ / 2 NCCN: National Comprehensive Cancer Network; NCCN Clinical Practice Guidelines in Oncology; Version 2.2022. Available at: www.nccn.org 3 Hesketh J. et al. J Clin Oncol. 2020 Aug 20;38(24):2782-2797. doi: 10.1200/JCO.20.01296. Epub 2020 Jul 13 For more information: Helsinn Media Contact: Paola Bonvicini, Group Head of Communication Lugano, Switzerland Tel: +41 (0) 91 985 21 21 Email: Info-hhc@helsinn.com For more information, please visit www.helsinn.com and follow us on Twitter and LinkedIn

上市批准临床结果临床研究

2022-11-29

·Business Wire

2022 Singapore Conference on Hybrid Applied Psychology (Singapore, Singapore - December 8-9, 2022) - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "2022 Singapore Conference on Applied Psychology 'LIVE'" conference has been added to ResearchAndMarkets.com's offering. A Hybrid Applied Psychology Conference The theme for SCAP 2022 is "Psychological Well-being". We invite researchers and practitioners from all fields of psychology research and practice to present and discuss recent innovations, trends, concerns, practical challenges encountered, and the solutions adopted in the field of Applied Psychology, with a special focus on 'Psychological Well-Being'. This can include clinical and non-clinical psychological well-being and we encourage submissions that cross disciplines, for example, psychological well-being in education and the workplace. Join us for SCAP 2022 at Holiday Inn Singapore Atrium, Singapore, and walk away with powerful knowledge that will empower you to forge the path for the future of Applied Psychology. Due to the persistence of COVID-19, the conference will be conducted in a 'Hybrid Format'. What Can You Expect? 2 Days 100% Top Singapore hospitality 70+ Internationally Recognised Speaker & Attendees 100% An opportunity for East-West science and practice collaborations Who Should Attend: Leading Academics PhD Candidates Practitioners Psychologists School Counsellors Therapists Thought leaders National and Local Government Provincial Government and Municipalities Speakers Dr. Tan Jing Hee Executive Director & Chairman Academic Board of East Asia Institute of Management Dr. Tan Jing Hee is the Deputy Chairman of the Management Council, Chairman of East Asia Institute of Management Academic Board. In 1973, he joined the Singapore Institute of Management, initially as Information, Publications and Research officer before moving into management development responsibilities. During his 25 years stay in the institute, he helped to build it into the premier HRD organisation in the region. While in SIM, Dr Tan was also involved in establishing enterprise-wide MBO systems in six medium and large organisations in Singapore. In 1987, he co-edited a book on Developing Managers In Asia, published by Addison-Wesley. Dr Tan was the Chief Operating Officer of SIM before leaving it to pursue other interests. In 1994, he wrote doctoral thesis on Developing A Factor Model of Management Work in Singapore, for which he was awarded his Ph.D from Henley Mangement College/Brunel University. Thomas Hunt Assoc. Professor, School of Human Sciences University of Derby Dr Hunt is an Assoc. Professor in the School of Human Sciences at the University of Derby in the UK. As an internationally recognised researcher in the field of mathematics anxiety, he has published several self-report measures and conducted a range of studies investigating the mechanisms that underpin the relationship between mathematics anxiety and performance. Dr Hunt's recent work has involved studying mathematics anxiety in an applied way, including drug dosage calculation anxiety in nursing students and statistics anxiety in students. He regularly works with a range of stakeholders to provide professional development workshops on the topic of mathematics anxiety, including strategies to reduce it. Carrie Childs Senior Lecturer in Psychology University of Derby Dr Carrie Childs is a Senior Lecturer in Psychology at the University of Derby, United Kingdom. She completed her Doctoral degree at Loughborough University. As a social psychologist with a strong qualitative background, she has focused her research on how language is used to negotiate relationships, actions and events in our everyday lives. Carrie has a long standing research interest in sexuality issues. Her past work has explored interaction between police officers and children reporting alleged sexual offences. More recently, she has turned her attentions to social constructions of sexuality, particularly the marginalisation of non-normative sexual practices and relationships. Her current work explores discursive constructions of 'sex addiction' in the accounts of women who identify as being sexually addicted. For more information about this conference visit https://www.researchandmarkets.com/r/3y06d1 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

高管变更

100 项与 University of Derby 相关的药物交易

登录后查看更多信息

100 项与 University of Derby 相关的转化医学

登录后查看更多信息